MHRA issues MS treatment risk update
Posted: Fri Mar 04, 2011 6:22 am
Risk of progressive multifocal leukoencephalopathy (PML) is increased in patients receiving natalizumab (Tysabri) who have had previous immunosuppressant treatment.
The UK medicines regulator MHRA has issued a new warning over the MS treatment natalizumab (Tysabri).
There is already a risk of progressive multifocal leukoencephalopathy (PML) with the treatment, which was known when it was given a licence. PML is a potentially deadly - but rare - progressive, and demyelinating brain disease.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905